Table 2.
Lung cancers by stage – number (%).
| Stage* | Screen Detected (%) | Subsequent Cancer# (screening arm) | Screening Total (%) | Control Total (%) |
|---|---|---|---|---|
| IA | 22 (52.4) | 15 (53.6) | 37 (52.9) | 8 (14.5) |
| IB | 5 (11.9) | 3 (10.7) | 8 (11.4) | 4 (7.3) |
| IIA | 7 (16.7) | _ | 7 (10.0) | 4 (7.3) |
| IIB | 1 (2.4) | 1 (3.6) | 2 (2.9) | 2 (3.6) |
| IIIA | 5 (11.9) | 2 (7.1) | 7 (10.0) | 4 (7.3) |
| IIIB | (0) | 2 (7.10 | 2 (2.9) | 6 (10.9) |
| IV | 2 (4.8) | 5 (17.9) | 7 (10.0) | 27 (49.1) |
| NA | 16 | 16 | 20 | |
| Total | 42 | 44 | 86 | 75 |
⁎
TNM version 7 staging; NA= not available from NCRAS, e.g. not staged (n=4) or during 2018-2019 (staging data not released at time of analysis, n=33); % refers to cancers with known staging only; # Subsequent cancer in screening arm are those detected subsequent to LD-CT screen(s) carried out per protocol.